The Regenerative Medicine market is experiencing substantial growth globally, fueled by increased R&D investments, a rise in clinical trials for innovative treatments such as stem cell and CAR-T cell therapies, and advancements in tissue-engineered products. This extensive market research report encapsulates the market's status and anticipates its trajectory, providing a roadmap for informed strategic planning and investment.
The report delves into the impact of market drivers and barriers such as high treatment costs and regulatory hurdles, offering a balanced perspective. Key market segments like musculoskeletal disorders, which hold the highest market share due to an expanding geriatric population and increasing number of stem cell research projects, are examined closely. Insights on growth regions such as the Asia Pacific and North America provide a geographical context to predictions, ensuring a global understanding of the Regenerative Medicine market.
With primary interviews from both the supply side and demand side, macro and micro-market perspectives are offered. Major players in the market such as Novartis AG, Biogen, and Sarepta Therapeutics are profiled, providing a view of the competitive landscape. This report will benefit market leaders, new entrants, and stakeholders by providing closest approximations of the market's revenue numbers, enabling them to strategize effectively for the future of Regenerative Medicine.
The regenerative medicine market is projected to reach USD 40.6 Billion by 2027 from USD 12.2 Billion in 2022, at a CAGR of 27.2% during the forecast period. Market growth is driven by the availability of funding and rising investments in R&D, increasing clinical trials for stem cell and CAR-T cell therapies, and rising advancements in tissue-engineered products. However, the high treatment cost of RM therapies and commercialization & regulatory are expected to restrain the market growth during the forecast period.
By application, the musculoskeletal disorders segment accounted for the largest share of the regenerative medicine market
Based on applications, the regenerative medicine market is segmented into musculoskeletal disorders, wound care, oncology, ocular disorders, dental, and other applications. In 2021, the musculoskeletal disorders segment accounted for the largest market share. This can be attributed to the rising prevalence of orthopedic diseases, the growing geriatric population, the increasing number of stem cell research projects, the growing number of clinical research/trials, and the rich pipeline of stem cell products for treating musculoskeletal disorders.
Asia Pacific: The fastest-growing region in the regenerative medicine market
The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, mainly due to increasing research activities in Asian countries, the availability of funding for research, and the growing number of biobanks and research centers are driving the growth of the Asia Pacific regenerative medicine market.
North America: the largest share of the regenerative medicine market
North America accounted for the largest share of the regenerative medicine market. Factors such as the to establishment of stem cell banking, tissue engineering , rise in demand for advanced technology-based treatments like stem cell technology, biologics, tissue engineering, and biomaterials.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 80% and Demand Side 20%
- By Designation: C-level - 25%, D-level - 20%, and Others - 55%
- By Region: North America -50%, Europe -20%, Asia-Pacific -20%, Latin America -5%, Middle East and Africa - 5%
- Novartis AG (Switzerland)
- Biogen (US)
- Sarepta Therapeutics, Inc. (US)
- Gilead Sciences, Inc. (US)
- Amgen, Inc. (US)
- Smith & Nephew plc (UK)
- MEDIPOST Co., Ltd. (South Korea)
- JCR Pharmaceuticals Co., Ltd (Japan)
- Takeda Pharmaceutical Company (Japan)
- CORESTEM Inc (South Korea)
- Vericel Corporation (US)
- MIMEDX (US)
- Organogenesis Inc. (US)
- Medtronic plc (US)
- Orthocell Ltd. (Australia)
- Mesoblast Ltd (Australia)
- BioRestorative Therapies (US)
- Pluri Inc, (Israel)
- Tegoscience (South Korea)
- Anterogen Co., Ltd. (South Korea)
- Bluebird Bio (US)
- APAC Biotech (India)
- Shenzhen Sibiono Genetech Co., Ltd. (China)
- Aspect Biosystems (Canada)
- Athersys, Inc. (US)
This report provides a detailed picture of the regenerative medicine market. It aims at estimating the size and future growth potential of the market across different segments, such as the product, applications, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall regenerative medicine market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
What is the estimated value of the Global Regenerative Medicine Market?
What is the growth rate of the Global Regenerative Medicine Market?
What is the forecasted size of the Global Regenerative Medicine Market?
Who are the key companies in the Global Regenerative Medicine Market?
|No. of Pages||192|
|Forecast Period||2022 - 2027|
| Estimated Market Value ( USD ||$ 12.2 Billion|
| Forecasted Market Value ( USD ||$ 40.6 Billion|
|Compound Annual Growth Rate||27.2%|
|No. of Companies Mentioned||25|
Table of Contents
1.2 Market Definition
1.2.1 Inclusions & Exclusions
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.7 Summary of Changes
2.1.1 Secondary Data
2.1.2 Primary Data
2.1.3 Market Data Estimation & Triangulation
2.2 Market Estimation Methodology
2.3 Growth Rate Assumptions/Growth Forecast
2.4 Insights from Primaries
2.5 Research Assumptions
2.6 Risk Assessment
5.2 Market Dynamics
5.3 Technology Analysis
5.4 Trends/Disruptions Impacting Customer's Business
5.5 Supply/Value Chain Analysis
5.6 Ecosystem/Market Map
5.7 Porters Five Forces Analysis
5.7.1 Threat of New Entrants
5.7.2 Threat of Substitutes
5.7.3 Bargaining Power of Suppliers
5.7.4 Bargaining Power of Buyers
5.7.5 Intensity of Competition Rivalry
5.8 Regulatory Landscape
5.8.1 Regulatory Bodies, Government Agencies and Other Organizations
5.9 Pricing Analysis
5.9.1 Average Selling Prices of Key Players, by Source
5.9.2 Average Selling Price Trend
5.10 Pipeline Analysis
5.11 Key Conferences & Events in 2022-2023
5.12 Key Stakeholders & Buying Criteria
6.2 Cell Therapy
6.2.1 Stem Cell Therapy
188.8.131.52 Autologous Therapy
184.108.40.206 Allogenic Therapy
6.2.2 Cord Blood/Progenitor Cell Therapies
6.2.3 Cell-Based Immunotherapy Products
6.3 Gene Therapy
6.4 Tissue Engineering
7.4 Dermatology & Wound Care
7.7 Cell Transplantations
7.8 Other Applications
8.2 North America
8.3.5 Rest of Europe
8.4.5 Rest of Asia-Pacific
8.5 Latin America
8.6 Middle East & Africa
9.2 Revenue Share Analysis of Top Market Players (2020/2021)
9.3 Market Share Analysis (2021)
9.4 Company Evaluation Quadrant
9.4.2 Emerging Leaders
9.4.3 Pervasive Players
9.4.5 Competitive Benchmarking
9.5 Start-Up/Sme Evaluation Quadrant
9.5.1 Progressive Companies
9.5.2 Starting Blocks
9.5.3 Responsive Companies
9.5.4 Dynamic Companies
9.6 Competitive Scenario
9.6.1 Product Launches
9.6.3 Other Developments
11.2 Knowledge Store: The Subscription Portal
11.3 Available Customizations
- 3M Group
- Amgen, Inc.
- Anterogen Co., Ltd.
- APAC Biotech
- Aspect Biosystems
- Bluebird Bio
- Corestem, Inc.
- Integra Lifesciences Holdings Corporation
- Kite Pharma
- Medipost Co., Ltd.
- Medtronic plc
- Mimedx Group
- Novartis Ag
- Organogenesis Inc.
- Orthocell Ltd.
- Shenzhen Sibiono Genetech Co., Ltd.
- Smith & Nephew plc
- Spark Therapeutics
- Stryker Corporation
- Takeda Pharmaceutical Company Limited
- Tego Science, Inc.
- Vericel Corporation
- Zimmer Biomet